Last reviewed · How we verify

NCT06279572

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

Recruiting now Last updated 1 April 2026
What this trial tests

trial testing Biospecimen Collection in Acute Myeloid Leukemia in 80 participants. Currently enrolling.

Timeline
22 April 2021
Primary endpoint
31 December 2027
31 December 2027

Quick facts

Lead sponsorMayo Clinic
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment80
Start date22 April 2021
Primary completion31 December 2027
Estimated completion31 December 2027
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the immune profile of patients receiving treatment with venetoclax plus azacitidine for acute myeloid leukemia (AML). Studying the information gathered from the immune profile from blood and bone marrow samples may help researchers understand the associated responses to the treatment of patients undergoing therapy of venetoclax plus azacitidine and create future immune based treatment approaches.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.
    Badar T, Knutson KL, Foran J, Gangat N, et al · · 2025 · cited 4× · PMID 39571168 · DOI 10.1182/bloodadvances.2024014553

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06279572.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing